CommentaryAngiotensin blockade for hypertension: a promise fulfilled
References (17)
- et al.
Renin and aldosterone and the pathogenesis of hypertensive vascular damage
Prog Cardiovasc Dis
(1974) - et al.
Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II
Lancet
(1971) - et al.
Angiotensin-II blockade in man by sarl-ala8-angiotensin II for understanding and treatment of high blood-pressure
Lancet
(1973) - et al.
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II
Lancet
(2000) - et al.
Essential hypertension: renin and aldosterone, heart attack and stroke
N Engl J Med
(1972) - et al.
Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension
JAMA
(1977) The sixth report of the Joint National Committee on prevention detection, evaluation and treatment of high blood pressure
Arch Intern Med
(1997)- et al.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators
N Engl J Med
(1992)
Cited by (43)
Motor sequela of adult and pediatric stroke: Imminent losses and ultimate gains
2023, Handbook of Clinical NeurologyIntegration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation
2018, European Journal of Medicinal ChemistryCitation Excerpt :Therefore, AT1 receptors and A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and such issues. Several non-peptide AT1 receptor antagonists have been described in the past few years, such as “sartans”, i.e. candesartan, irbesartan, valsartan, telmisartan and eprosartan; which are effective in the treatment of hypertension and associated cardiovascular disorders [9–15]. These approved drugs differ in their structure, pharmacological profile and efficacy.
Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives
2018, Journal of Molecular Graphics and ModellingCitation Excerpt :Therefore, AT1 receptors and the A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and such diseases. In the past few years, several non-peptide AT1 receptor antagonists have been described as “sartans”, which are effective in the treatment of hypertension and cardiovascular disorders [9–15]. These approved drugs differ in their structure, pharmacological profile and efficacy.
Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives
2017, Journal of Molecular Graphics and ModellingTherapeutic role of toll-like receptor modification in cardiovascular dysfunction
2013, Vascular PharmacologyCitation Excerpt :In an animal model of chronic stress, Eritoran inhibited NFkB activity and reduced stress-related myocardial injury (Wang et al., 2011b). Angiotensin II receptor blockers are commonly used in patients with cardiovascular diseases to lower blood pressure (Dahlof et al., 2002; Brunner and Gavras, 2002). In addition to its vasoconstrictor activity, angiotensin II increases reactive oxygen species and inflammatory mediators such as IL-6 and TNF-alpha.
Modern Drug Discovery and Development
2009, Clinical and Translational Science